🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We conclude that isodose MHFRT should be the optimal MHFRT regimen for prostate cancer.

Another fantastic and high-level MARCAP analysis. Amazing work!

🚀Ph2 SMART ONE trial in press 🔹1-fx SBRT on 0.35T MR-Linac 🔹2/3 targets abd/pelvis, 1/3 lung 🔹🔥🔥 plans!! Median GTV mean dose: adrenal 32.3 Gy, LN 31.7 Gy, liver 45.4 Gy, lung 42.8 Gy 🔹Median time 53 min, ART routine 🔹1-yr LC 96.2%, 1-yr OS 86.3% redjournal.org/article/S0360-…

Congrats guys on the prospective data! I would have expected these findings of identical efficacy, but the important clinical question is regarding long term tox, with the non-comparative data supporting HDR. ASCENDE-SBRT with HDR may prove to be the ultimate dose-escalation

Every Other Day or Once a Week: Long-term Oncological Outcomes in the Phase 2 PATRIOT Trial of Prostate Stereotacti… pubmed.ncbi.nlm.nih.gov/40288917/

🚨10y results of HYPO RT PC at #ESTRO25 Hypofractionated #prostatecancer RT (42,7/7) vs conv fractionated RT 1. Non inferior for FFS (even better?) 2. Similar bPFS, DMFS, ADT use, OS 3. Similar GU/GI tox (except transient flare at 1y for UHF)

HYPO RT 10 years follow up shows similar toxicities and outcome with 7 fraction vs. 39 fraction #estro Amar Kishan Vedang Murthy

🔥⚡️🚀 First prospective comparison of SBRT vs HDR-BT in prostate cancer (SHERBET study): SBRT shows superior long-term efficacy & lower BCF. Two-fraction HDR-BT w/o ADT? Only in trials for intermediate-risk pts. Great work from Sunnybrook team! #RadOnc #GU25 Dr. Andrew Loblaw

Great work doing it in a prospective randomized fashion! Working on getting our experience published as well. The more data the better!

KEYNOTE-641 & KEYNOTE-991 in Prostate Cancer What happens when you combine immunotherapy (pembrolizumab) with androgen receptor inhibitors (enzalutamide) in mCRPC & mHSPC? Let’s break down 2 major negative trials that teach us important lessons.👇 ⸻ 🔬 KEYNOTE-641: 📍

📢This might just be THE DEFINITIVE meta-analysis of PSMA PET for #prostatecancer recurrence. 🚨Meta-analysis of 43 studies (n=8,119) ⬆️Sensitivity from 48% at PSA 0.2–0.5 ng/ml to >90% at PSA >2. Congrats Declan Murphy marlon perera + team European Association of Urology (EAU)! ➡️link shorturl.at/unfn5

🚨 #ASCO25 Update 🚨 🧪 PDIGREE trial, n=1111, intermediate and poor risk #kidneycancer 🧬 Ipi + Nivo in mccRCC (Step 1 analysis) 📈 5-year OS: 71% / 5-year PFS: 34% 💪🏽 trial design - survived 10 years of new agents! 🔄 Potential to refine adaptive treatment strategies! ASCO

EXTEND showed us that MDT + ADT > ADT RADIOSA showed MDT + ADT > MDT. STORM / PEACE-V showed ENI + MDT + ADT > MDT + ADT All studies had some novel imaging defined mHSPC (STORM was 100% novel) Can we just accept that MDT (+/- elective RT) + ADT is better than either?!?

Stereotactic Ablative Body Radiotherapy for Oligoprogressive Estrogen Receptor–Positive Breast Cancer (TROG 20.03 AVATAR): A Phase II Prospective Multicenter Trial | JCO Oncology Advances ascopubs.org/doi/10.1200/OA…

These are key questions. Pelvic ENI and MDT that can preclude the need for ADT can substantially increase pt QoL bc at that point its too often the ADT at the root of bothersome side effects. Smarter, individualized, targeted RT to obviate ADT = 💪

Great start. I've gone through the evolution of decreasing from 42 ➡️33 ➡️20, and as the data matures, really looking forward to getting these guys down to 5, just like the definitive cases 💪

Robotic Stereotactic Body Radiation Therapy for High-Risk Prostate Cancer: The Georgetown University Experience cureus.com/articles/35885…

Sean McBride Sean McGuire Matthew Ward Sean Collins Prostate SBRT @ USF Health Alfonso Gomez-Iturriaga Why is this? Sadly < 10% of RCTs are surgical in PCa. This number is shrinking over time. AI models smart enough now to see past the ocean of low quality data. Surgery valuable tool. Need surgical leaders to unite and push against the non-EBM adoption of things without data to

Challenging to follow both clinically and financially. Pts are also getting older and often hard to attribute for ex worsening GU fxn in a pt in their 70s-80s. ProTect good example of AS/RT/RP. Need more LT tox studies!

Thanks Sean! Great work and nice follow up. The data is young still (I pressed re-start on my life/career 4 yrs ago 😊) but any day our 5-fx HR Pca with ENI tox data is coming out. Dovetails nicely w/ all the great work from SHARP 💪 @amarukishan Vedang Murthy Dr. Andrew Loblaw